About REGENXBIO Inc.
https://www.regenxbio.comREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
CEO
Curran M. Simpson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
RBC Capital
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.61M
Value:$128.71M
BLACKROCK, INC.
Shares:6.37M
Value:$95.24M
REDMILE GROUP, LLC
Shares:4.69M
Value:$70.17M
Summary
Showing Top 3 of 219
About REGENXBIO Inc.
https://www.regenxbio.comREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $29.73M ▲ | $20.32M ▼ | $-61.94M ▲ | -208.32% ▲ | $-1.2 ▲ | $-44.89M ▲ |
| Q2-2025 | $21.36M ▼ | $75.52M ▲ | $-70.87M ▼ | -331.81% ▼ | $-1.38 ▼ | $-55.97M ▼ |
| Q1-2025 | $89.01M ▲ | $73.45M ▲ | $6.08M ▲ | 6.83% ▲ | $0.12 ▲ | $18.61M ▲ |
| Q4-2024 | $21.21M ▼ | $66.26M ▼ | $-51.19M ▲ | -241.28% ▲ | $-1.01 ▲ | $-37.75M ▲ |
| Q3-2024 | $24.2M | $73.89M | $-59.6M | -246.3% | $-1.17 | $-54.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $274.2M ▼ | $525.2M ▼ | $363.75M ▼ | $161.45M ▼ |
| Q2-2025 | $323.3M ▲ | $581.03M ▲ | $367.35M ▲ | $213.68M ▼ |
| Q1-2025 | $267.87M ▲ | $490.93M ▲ | $216.73M ▲ | $274.2M ▲ |
| Q4-2024 | $234.69M ▼ | $465.99M ▼ | $206.34M ▼ | $259.65M ▼ |
| Q3-2024 | $255.46M | $519.11M | $217.7M | $301.42M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-61.94M ▲ | $-55.96M ▼ | $42.29M ▲ | $-7.08M ▼ | $-20.76M ▲ | $-56.45M ▼ |
| Q2-2025 | $-70.87M ▼ | $-49.34M ▼ | $-140.44M ▼ | $139.23M ▲ | $-50.55M ▼ | $-49.73M ▼ |
| Q1-2025 | $6.08M ▲ | $33.63M ▲ | $44.74M ▲ | $-5.79M ▲ | $72.58M ▲ | $32.6M ▲ |
| Q4-2024 | $-51.19M ▲ | $-31.62M ▲ | $40.27M ▼ | $-7.74M ▲ | $909K ▲ | $-32.7M ▲ |
| Q3-2024 | $-59.6M | $-40.55M | $50.26M | $-10.86M | $-1.15M | $-40.88M |
Revenue by Products
| Product | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 License and Service | $20.00M ▲ | $20.00M ▲ | $90.00M ▲ | $20.00M ▼ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $10.00M ▲ |
CEO
Curran M. Simpson
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 111
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Stifel
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Leerink Partners
Outperform
RBC Capital
Outperform
Barclays
Overweight
Grade Summary
Showing Top 6 of 8
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:8.61M
Value:$128.71M
BLACKROCK, INC.
Shares:6.37M
Value:$95.24M
REDMILE GROUP, LLC
Shares:4.69M
Value:$70.17M
Summary
Showing Top 3 of 219